{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-006800","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.114203+00:00","generated_at":"2026-06-08T13:14:37.687366+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cassava Sciences completes Phase 3 enrollment for simufilam; Q3 net loss $25.7M","bullets":["Enrollment completed: 1,929 patients randomized across two Phase 3 trials of simufilam for Alzheimer's.","Top-line results expected year-end 2024 (52-week trial) and mid-2025 (76-week trial).","Cash and equivalents $142.4M at Sept 30, 2023; no debt.","Q3 net loss $25.7M ($0.61/sh) vs $20.3M ($0.51/sh) in Q3 2022, driven by higher clinical costs.","Interim MRI safety data suggests simufilam not associated with ARIA; DSMB recommends continuation."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-006800","json":"https://secwatch.observer/filing/0001171843-23-006800.json","markdown":"https://secwatch.observer/filing/0001171843-23-006800.md","text":"https://secwatch.observer/filing/0001171843-23-006800.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000117184323006800/0001171843-23-006800-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000117184323006800/f8k_110723.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T13:14:37.687366+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5a916bee756bf795af7b155e64f0353f9390ebc4","claim":"FILANA THERAPEUTICS, INC. reported the third quarter ended September 30, 2023 results: net income $25.7 million, or $0.61 per share, EPS $0.61 per share.","evidence_excerpt":"Net loss was $25.7 million, or $0.61 per share. This compares to a net loss of $20.3 million, or $0.51 per share, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000117184323006800/0001171843-23-006800-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"$25.7 million, or $0.61 per share"},{"label":"EPS","value":"$0.61 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}